Differential effect of azidothymidine on resting and activated cells: potentiality of this drug for treatment of post-transfusion graft-versus-host disease.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Research Communications in Molecular Pathology and Pharmacology

• Publication date

  1998-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 9667067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones.

  1997cited by this paper
• Identification of the target molecule of cytotoxic T cells presumably responsible for development of transfusion-associated graft-versus-host disease.

  1996cited by this paper
• Analysis of risk factors for post-transfusion graft-versus-host disease in Japan. Japanese Red Cross PT-GVHD Study Group.

  1994cited by this paper
• Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

  1994cited by this paper
• Zidovudine Pharmacokinetics During Pregnancy

  1992cited by this paper
• Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan.

  1989cited by this paper
• Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis.

  1989cited by this paper
• Post-transfusion graft-versus-host disease after open heart surgery.

  1986cited by this paper
• Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine

  1986cited by this paper

• Reduced HIV‐stimulated T‐helper cell reactivity in cord blood with short‐course antiretroviral treatment for prevention of maternal–infant transmission

  2001cites this paper